Familial ALS/FTD-associated RNA-binding deficient TDP-43 mutants cause neuronal and synaptic transcript dysregulation in vitro
Open accessPublished version of a preprint
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index; none of the 84 sources its claims cite is checked for support yet.
Abstract
TDP-43 is an RNA-binding protein constituting the pathological inclusions observed in ~ 95% of ALS and ~ 50% of FTD patients. In ALS and FTD, TDP-43 mislocalises to the cytoplasm and forms insoluble, hyperphosphorylated and ubiquitinated aggregates that enhance cytotoxicity and contribute to neurodegeneration. Despite its primary role as an RNA/DNA-binding protein, how RNA-binding deficiencies contribute to disease onset and progression are little understood. Among many identified familial mutations in TDP-43 causing ALS/FTD, only two mutations cause an RNA-binding deficiency, K181E and K263E. In this study, we used CRISPR/Cas9 to knock-in the two disease-linked RNA-binding deficient mutations in SH-SY5Y cells, generating both homozygous and heterozygous versions of the mutant TDP-43 to investigate TDP-43-mediated neuronal disruption. Significant changes were identified in the transcriptomic profiles of these cells, in particular, between K181E homozygous and heterozygous cells, with the most affected genes involved in neuronal differentiation and synaptic pathways. This result was validated in cell studies where the neuronal differentiation efficiency and neurite morphology were compromised in TDP-43 cells compared to unmodified control. Interestingly, divergent neuronal regulation was observed in K181E-TDP-43 homozygous and heterozygous cells, suggesting a more complex signalling network associated with TDP-43 genotypes and expression level which warrants further study. Overall, our data using cell models expressing the ALS/FTD disease-causing RNA-binding deficient TDP-43 mutations at endogenous levels show a robust impact on transcriptomic profiles at the whole gene and transcript isoform level that compromise neuronal differentiation and processing, providing further insights on TDP-43-mediated neurodegeneration.
Overview
CoChat Summary
TL;DR
CRISPR/Cas9 knock-in of the ALS/FTD-associated RNA-binding-deficient TDP-43 mutants K181E and K263E in SH-SY5Y cells caused transcriptomic and isoform dysregulation, especially in neuronal and synaptic pathways. K181E homozygous and heterozygous cells showed opposing expression patterns, with functional consequences for neuronal differentiation and neurite growth.
Key findings
- K181E-TDP-43 cells showed 233 differentially expressed genes (DEGs) in homozygous and 167 in heterozygous cells versus wild-type control (q<0.1), while 997 genes differed significantly between K181E homozygous and heterozygous cells (q<0.05).
- Neuronal/synaptic genes were down-regulated in K181E homozygous cells but up-regulated in K181E heterozygous cells, including known TDP-43 targets STMN2, UNC13A and NPTX2; K263E cells showed no significant DEGs in the undifferentiated state.
- Isoform switching analysis identified ~7000 significant isoform changes in K181E homozygous and ~400 in K181E heterozygous cells versus wild-type (q<0.05), and ~10,000 between K181E homozygous and heterozygous cells; K181E homozygous cells showed a complete switch from canonical DCTN1-228 to DCTN1-203.
- Functionally, K181E homozygous cells had reduced MAP2 staining and reduced neurite length, whereas K181E heterozygous cells showed increased MAP2 staining and longer neurites in the undifferentiated condition; K263E cells showed differentiation deficits after differentiation began.
Methods
- CRISPR/Cas9 nucleofection with gRNA and HDR ssODN was used to introduce K181E or K263E into TARDBP in SH-SY5Y cells; homozygous and heterozygous clones were validated by Sanger sequencing, TARDBP cDNA integrity, Poldip3 splicing, TDP-43 immunofluorescence and cleaved caspase-3 viability assays.
- Bulk RNA-seq was performed on three independent RNA extractions per CRISPR clone and wild-type SH-SY5Y cells; libraries were poly(A)-selected and sequenced on NovaSeq 6000 (2x150-bp reads, minimum 30 million read pairs per sample), with analysis by kallisto v0.48, tximport, sleuth, fgsea/MSigDB and IsoformSwitchAnalyzeR.
- SH-SY5Y differentiation used retinoic acid followed by BDNF; immunofluorescence for MAP2 and beta-III-tubulin, RT-PCR for MAP2 and selected genes, and neurite tracing with NeuronJ on MAP2-stained cells (minimum 30 cells across three repeats) were used for functional validation.
Limitations
- Stated: the extent of disruption correlating with ageing and subsequent challenges still needs further investigation; how neurodevelopmental and neurodegenerative links may develop is not understood; no overt nuclear aggregates were seen at endogenous expression, possibly due to lack of challenge or insufficient expression to drive aggregation.
- Evident: all experiments are in the SH-SY5Y neuroblastoma cell line in vitro, not patient tissue or in vivo models; K263E showed no significant DEGs in the undifferentiated state, so transcriptomic conclusions are largely driven by K181E; only two RNA-binding-deficient TDP-43 mutations were studied.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
0 Valid · 1 Not valid · 44 Not checked · 73 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using a significance cut-off of q<0.1, we found no significant differential expressed genes (DEGs) between the K263E-TDP-43 cells and control cells (Supplementary Figure 2).”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Differences in K181E-TDP-43 homozygous and heterozygous transcriptomic profiles in comparison to wild-type cells observed by RNA-seq analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When comparing K181E-TDP-43 cells with control, 233 and 167 DEGs were identified in K181E-TDP-43 homozygous and heterozygous cells respectively (q<0.1; Figure 2A-B, Supplementary Data 1).”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Differences in K181E-TDP-43 homozygous and heterozygous transcriptomic profiles in comparison to wild-type cells observed by RNA-seq analysis.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other significant pathways down-regulated in K181E-TDP-43 homozygous cells included those related to transport, secretion and general biogenesis and signalling (Figure 3C; Supplementary Data 1), again indicating a potential functional compromise in neurite establishment and neuronal communication.”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Neuronal and synaptic pathways are significantly down-regulated in K181E-TDP-43 homozygous cells.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The known TDP-43 targets implicated in ALS disease pathogenesis, STMN2, UNC13A and NPTX2 (13)(14)(15)(16)34), also show this similar opposing expression pattern, being down-regulated in K181E-TDP-43 homozygous cells but up-regulated in K181E-TDP-43 heterozygous cells (Figure 3D).”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Neuronal and synaptic pathways are significantly down-regulated in K181E-TDP-43 homozygous cells.
What the sources say
- Not matchedcites (13)(14)(15)(16)34)
This doesn’t read as a citation we can look up.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transcriptomic comparison revealed significant gene expression differences in neuronal and synaptic genes between K181E-TDP-43 homozygous and heterozygous cells compared to wild-type control.”
- Also stated in: § Abstract · plain
“Significant changes were identified in the transcriptomic profiles of these cells, in particular, between K181E homozygous and heterozygous cells, with the most affected genes involved in neuronal differentiation and synaptic pathways.”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Introduction
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
51 more claims
Create a free account to see all 118 claims and to verify the 66 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 23
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > SH-SY5Y differentiation
“Medium was refreshed every 2 days and cells harvested or fixed after 4 days in BDNF for further analysis.”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Dosage-dependent opposing effect of K181E-TDP-43
“fully differentiated (5 days after BDNF treatment).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Dosage-dependent opposing effect of K181E-TDP-43
“All DEGs identified in K181E-TDP-43 homozygous vs WT(B) and K181E-TDP-43 heterozygous vs WT (C) are plotted in the heatmap.”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Dosage-dependent opposing effect of K181E-TDP-43
“A-B.Volcano plots showing genes with significantly altered expression in K181E-TDP-43 homozygous cells (A) or heterozygous cells (B) relative to un-edited control SH-SY5Y cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Gene expression profiling
“Gene Set Enrichment Analysis (GSEA) was run using the R package fgsea (27) using the prerank setting based on πvalues (-log10(q-value) x log2(fold change)) (28).”
§ Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic dysregulation in vitro > Dosage-dependent opposing effect of K181E-TDP-43
“πvalues (-log10(p-value) x log2(fold change)) were used as the rank of significance.”
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences
Soneson, C., Love, M. I., & Robinson, M. D. (2015) · F1000Research · doi:10.12688/f1000research.7563.1 · Cited by 3,929
Fast gene set enrichment analysis
Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M. N., & Sergushichev, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060012 · Cited by 3,454
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Research works printed but not linked: 4
- Mulligan, M.R. and Bicknell, L.S. (2023) The molecular genetics of nELAVL in brain development and disease. European Journal of Human Genetics, 31, 1209-1217.
- Basha, M.R., Wei, W., Bakheet, S.A., Benitez, N., Siddiqi, H.K., Ge, Y.W., Lahiri, D.K. and Zawia, N.H. (2005) The fetal basis of amyloidogenesis: Exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. Journal of Neuroscience, 25, 823-829.
- Stillman, B. and Stewart, D. (2007) Regulatory RNAs. Cold Spring Harbor Laboratory Press, 978, 313-320.
- Andrews, S. (2019) FastQC: A quality control tool for high throughput sequence data. FastQC: A quality control tool for high throughput sequence data.
Cited by
RNA Degradation in Pluripotent Stem Cells: Mechanisms, Crosstalk, and Fate Regulation
Jeong, S., Oh, M., Han, J., & Kim, S.-K. (2025) · Cells · doi:10.3390/cells14201634 · Cited by 5
Multimodal strategies for diagnosis, stratification, and therapeutic monitoring in ALS
López‐Blanch, R., Oriol‐Caballo, M., Estrela, J. M., & Obrador, E. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106727 · Cited by 3
TDP-43: [GU]-ardian of the transcriptome
Sinha, I. R., Atkinson, A. L., Irwin, K. E., Ling, J. P., & Wong, P. C. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00944-2 · Cited by 2
McLellan, C., Campos‐Melo, D., Hammond, R. R., & Strong, M. J. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03005-6
Crossroad of motor neuron disease and dementia: Insights from TDP-43 RNA-binding deficiency
Magarotto, M., & Chen, H.-J. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01285
Self-citation
Metadata
- Authors
- Magarotto, M., Gawne, R. T., Vilkaite, G., Beltrami, M., Mason, A. S., & Chen, H.-J.
- Affiliations
- University of York (GB)
- Corresponding author
- Chen, Han-Jou
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-06-30
- Volume
- 34
- Issue
- 17
- Pages
- 1480-1494
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W4411927652
- Cited by
- 5
- References
- 100
- Citations by year
- 2026: 4 · 2025: 1
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Human Molecular Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- British Heart Foundation and Diabetes UK (SBF006\1088)
- ASM’s York Against Cancer
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- TDP-43, amyotrophic lateral sclerosis, frontotemporal dementia, familial mutation, transcriptome dysregulation, neuronal differentiation, synaptic dysfunction, neurite morphology, neurodegeneration, SH-SY5Y cells, CRISPR/Cas9 knock-in
- MeSH terms
- Amyotrophic Lateral Sclerosis, Cell Differentiation, DNA-Binding Proteins, Humans, Mutation, Neurons, Synapses, RNA-Binding Proteins, Cell Line, Tumor, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.